Nexo Therapeutics is focused on developing innovative cancer therapies by leveraging two specialized platforms that bridge the gap between target biology and ligand discovery. Their approach addresses the challenges of drug discovery, particularly for elusive cancer targets, by utilizing INFINI-T chimeric proteins and chemical genetics. This biology engine enables the modulation of target proteins through small molecules, providing critical insights into the pharmacological parameters necessary for effective therapeutic intervention. By integrating these insights, Nexo can optimize lead compounds through medicinal chemistry, ultimately aiming to create effective treatments for patients.

In addition to their chimeric protein platform, Nexo employs a robust ligand discovery engine powered by a library of over 10,000 covalent fragments. This diverse collection allows for the targeting of all ligandable amino acids, enhancing the potential for discovering effective drug candidates. By utilizing protein structure and computational methods, Nexo optimizes these covalent hits into viable leads, ensuring that the small molecule modalities align with the specific biology of the targets. This dual-platform strategy positions Nexo Therapeutics to tackle previously intractable cancer targets and advance the development of novel therapies.

United States

Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies. Nexo combines covalent ligand discovery and chemical biology with expertise in cancer biology and medicinal chemistry to target fundamental drivers of cancer by innovative approaches. With facilities in Golden, CO and Watertown, MA, Nexo is led by Founder and CEO, Andrew Phillips, PhD. For more information, please visit www.nexotx.com.

Nexo Therapeutics

Company Details